• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

    2.690 +0.080 (+3.07%)
    Streaming Delayed Price Updated: 2:59 PM EST, Feb 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Acumen Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
    Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's Disease 
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
    Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
    From Climb Bio, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
    Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug 
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.